Hygromycin B

立即咨询

Hygromycin B

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

31282-04-9

包装与价格：

包装	价格(元)
200mg	电议
500mg	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	527.5
Cas No.	31282-04-9
Formula	C₂₀H₃₇N₃O₁₃
Solubility	≥26.38 mg/mL in H2O; ≥5.35 mg/mL in EtOH; ≥9.14 mg/mL in DMSO
Chemical Name	(3'R,3aS,4S,4'R,5'R,6R,6'R,7S,7aS)-4-[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1S)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol
Canonical SMILES	CNC1CC(C(C(C1O)OC2C3C(C(C(O2)CO)O)OC4(O3)C(C(C(C(O4)C(CO)N)O)O)O)O)N
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Hygromycin B是一种选择性抗生素，用于治疗和预防细菌感染。

Hygromycin B是一种抗生素，对大多数细菌、真菌和高等真核细胞有效。Hygromycin B具有30S亚基，含有单个结合位点，这与它的单相作用一致。该结合位点位于螺旋的大沟内，具有高度序列特异性。Hygromycin B通过抑制延长过程中的易位步骤和促使70S核糖体mRNA的错误翻译，抑制蛋白质合成[1]。在70S核糖体中，Hygromycin B选择性抑制核糖体ATP酶（RbbA）的活性，将RbbA从70S核糖体释放，RbbA增强16S rRNA开关螺旋区域A889和G890的反应性。另外，Hygromycin B可以保护解码区域的G1494和A1408。

参考文献：
[1]. Brodersen DE, Clemons WM Jr, Carter AP, et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell, 2000, 103(7): 1143-1154.
[2]. Ganoza MC, Kiel MC. A ribosomal ATPase is a target for hygromycin B inhibition on Escherichia coli ribosomes. Antimicrob Agents Chemother, 2001, 45(10): 2813-2819.

试验操作

Cell experiment:[1]
Cell lines	Mouse L cells
Reaction Conditions	200 μg/ml hygromycin B for 2 ~ 6 weeks
Applications	Hygromycin B was used for resistance selection in mouse L cells transfected withEscherichia coligenes coding for resistance to the aminocyclitol antibiotics hygromycin B.
Animal experiment:[2]
Animal models	Four-week-old BALB/c mice susceptible to MHV-A59 infection
Dosage form	0 ~ 10 μmol/kg Intraperitoneal (i.p.) injection
Applications	A single injection of hygromycin B reduced the number of lesions in the livers of MHV-A59-inoculated mice. Higher doses of the drug appeared to be slightly more effective at reducing virus-induced lesions.
Note	The technical data provided above is for reference only.
	References: 1. Santerre RF, Allen NE, Hobbs JN Jr, et al. Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene, 1984, 30(1-3): 147-156. 2. Macintyre G, Curry B, Wong F, et al. Hygromycin B therapy of a murine coronaviral hepatitis. Antimicrobial Agents and Chemotherapy, 1991, 35(10): 2125-2127.